De Novo
DEN210011: Invitae Common Hereditary Cancers Panel
FDA De Novo · invitae corporation · decided Sep 29, 2023
Key facts
| De Novo number | DEN210011 |
|---|---|
| Device name | Invitae Common Hereditary Cancers Panel |
| Applicant | invitae corporation |
| Product code | QVU |
| Date received | Mar 29, 2021 |
| Decision date | Sep 29, 2023 |
| Decision | granted (DENG) |
| FDA classification | Class II |
| Review panel | Pathology |
| FEI number | 3013248161 |
At a glance
- None Later 510(k)s citing this De Novo
- None UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
- No Decision summary on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About De Novo classification requests
The De Novo pathway classifies novel low- to moderate-risk devices that have no legally marketed predicate; each granted request creates a new classification regulation and product code.
Source: U.S. Food and Drug Administration (FDA), De Novo database · Source date: